N. Campbell

发表

A Novel Classification of Lung Cancer into Molecular Subtypes

Jeff Shrager, R. Bueno, R. Salgia, 2012, PloS one.

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Hung-Ming Wang, R. Greil, K. Harrington, 2019, The Lancet.

High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML)

R. Larson, D. Huo, W. Stock, 2012, Leukemia & lymphoma.

68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial

N. Lawrentschuk, D. Murphy, M. Frydenberg, 2021, World Journal of Urology.

Drainage of right superior vena cava into both atria. Review of the literature and description of a case presenting with polycythemia and paradoxical embolization.

E. Shapiro, O. Thilenius, N. Campbell, 1981, Circulation.

Neoadjuvant treatment of esophageal cancer.

V. Villaflor, N. Campbell, 2010, World journal of gastroenterology.

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma

Ravi Salgia, Nicholas Campbell, Sonali M. Smith, 2012, Targeted Oncology.

PSA and beyond: Biomarkers in prostate cancer

S. Goldenberg, N. Campbell, James G. Huang, 2014 .

The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative

R. Salgia, T. Hensing, G. Carey, 2016, Cureus.

Update on malignant pleural mesothelioma.

H. Kindler, N. Campbell, Nicholas Paul Campbell, 2011, Seminars in respiratory and critical care medicine.

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database

Eneida A. Mendonça, Ravi Salgia, Rifat Hasina, 2011, Journal of Clinical Bioinformatics.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck

T. Hensing, M. Bhayani, N. Campbell, 2016, Expert review of anticancer therapy.

Personalized treatment of lung cancer.

M. Maitland, R. Salgia, T. Hensing, 2011, Seminars in oncology.

Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.

C. Antonescu, D. Gandara, E. Vokes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.

Cheryl C Nocon, Thomas L. Carroll, A. D. Friedman, 2021 .

A phase II study of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal, and/or pulmonary involvement.

Thomas L. Carroll, A. D. Friedman, S. Pai, 2019, Journal of Clinical Oncology.

Association of a Proactive Swallowing Rehabilitation Program With Feeding Tube Placement in Patients Treated for Pharyngeal Cancer

Cheryl C Nocon, M. Bhayani, N. Campbell, 2018, JAMA otolaryngology-- head & neck surgery.

Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST).

C. Antonescu, D. Gandara, E. Vokes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).

R. Larson, D. Huo, W. Stock, 2009 .